Slater J D, Lunn D P, Horohov D W, Antczak D F, Babiuk L, Breathnach C, Chang Y-W, Davis-Poynter N, Edington N, Ellis S, Foote C, Goehring L, Kohn C W, Kydd J, Matsumura T, Minke J, Morley P, Mumford J, Neubauer T, O'Callaghan D, Osterrieder K, Reed S, Smith K, Townsend H, van der Meulen K, Whalley M, Wilson W D
Department of Veterinary Clinical Sciences, Royal Veterinary College, Hatfield, Hertfordshire AL9 7TA, UK.
Vet Immunol Immunopathol. 2006 May 15;111(1-2):3-13. doi: 10.1016/j.vetimm.2006.01.004. Epub 2006 Mar 20.
Amongst the infectious diseases that threaten equine health, herpesviral infections remain a world wide cause of serious morbidity and mortality. Equine herpesvirus-1 infection is the most important pathogen, causing an array of disorders including epidemic respiratory disease abortion, neonatal foal death, myeloencephalopathy and chorioretinopathy. Despite intense scientific investigation, extensive use of vaccination, and established codes of practice for control of disease outbreaks, infection and disease remain common. While equine herpesvirus-1 infection remains a daunting challenge for immunoprophylaxis, many critical advances in equine immunology have resulted in studies of this virus, particularly related to MHC-restricted cytotoxicity in the horse. A workshop was convened in San Gimignano, Tuscany, Italy in June 2004, to bring together clinical and basic researchers in the field of equine herpesvirus-1 study to discuss the latest advances and future prospects for improving our understanding of these diseases, and equine immunity to herpesviral infection. This report highlights the new information that was the focus of this workshop, and is intended to summarize this material and identify the critical questions in the field.
